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followed by mandatory 90-day (36.85%, 35.51%) and 30-day
retail program (33.73%, 32.41%) in both claims level and
patient level, respectively. However, only the GDR differences
between voluntary 90-day retail program and 30-day retail
program were found to be statistically signiﬁcant for all three
therapeutic classes at both claim and patient level (P < 0.05).
CONCLUSION: The study showed comparable results indicat-
ing that there were no drastic difference in the utilization of
generic drug by claims and patients between mandatory 90-day
retail program and 30-day retail program. However, voluntary
90-day retail program showed a signiﬁcantly higher share of
generic utilization than 30-day retail program.
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OBJECTIVES: To estimate the prevalence of clinically important
potential drug-drug interactions (DDIs) among residents of
Regione Emilia Romagna (RER), Italy. METHODS: We con-
ducted a retrospective cohort study using the 2004 outpatient
prescription claims database of RER, which was linked to the
2004 demographic ﬁle of 4,222,165 RER residents. Using a pre-
viously published list of clinically important potential DDIs as
framework, we identiﬁed 11 potential DDIs that could be cap-
tured through the RER database because both drugs were reim-
bursed by the 2004 Italian National Formulary. A potential DDI
was deﬁned as the presence of a minimum 5-day overlap in days
supply for each of the drugs in an interacting pair. The World
Health Organization Anatomical Therapeutic Classiﬁcation/
Deﬁned Daily Dose System was used to determine a proxy
measure of days supply for each drug. The one-year prevalence
of each potential DDI was quantiﬁed at the patient level.
RESULTS: In 2004, the 11 potential DDIs occurred 7,379 times
in 6,681 RER residents, yielding a one-year prevalence of 158.2
cases per 100,000 individuals. The mean age of those exposed
to potential DDIs was 74.1 (SD = 10.8) years and about 52%
were female. Of those exposed, 559 (8.4%) were exposed to 2
potential DDIs and 64 (1.0%) were exposed to at least 3 poten-
tial DDIs. The most commonly identiﬁed potentially interacting
medication pairs were warfarin and nonsteroidal anti-inﬂamma-
tory drugs (5,616 cases), theophylline/aminophylline and the 
ﬂuoroquinolones ciproﬂoxacin and ﬂuvoxamine (759), warfarin
and barbiturates (530), and warfarin and ﬁbric acids (339).
CONCLUSION: To our knowledge, this is the ﬁrst large popu-
lation-based study in Italy documenting the prevalence of poten-
tial DDIs. A substantial number of clinically important potential
DDIs were identiﬁed, particularly among warfarin users. DDIs
are predictable, hence preventable. Awareness of the most com-
monly occurring potential DDIs can help practitioners prevent
coadministration of these potentially dangerous medication 
combinations.
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OBJECTIVES: To estimate the beneﬁciary’s out-of-pocket spend-
ing to ﬁll their prescriptions in 2003 at the Saudi Ministry of
Health (MOH) hospital outpatient clinics. METHODS: A non-
randomized sample of 19 hospitals participated in a study inves-
tigating the inﬂuence of pharmacy and therapeutics (P&T) com-
mittee and pharmacy information system (PIS) on patients’
access to and utilization of prescription drugs. These hospitals
were selected deliberately to represent different levels of PIS and
P&T committee characteristics based on the results of a descrip-
tive study of all 127 non-specialized MOH hospitals. Systematic
sampling was used to audit 150 patients prescription papers
(orders) from each hospital outpatient pharmacy. The cost esti-
mates based on community pharmacy market price. RESULTS:
Of 2850 audited patient records, only 202(7.1%) had a free
access rate less than 100 percent and have to pay out-of-pocket.
The mean of out-of-pocket spending is $16.5 (s = 34.4)to ﬁll pre-
scriptions. Patients diagnosed with cardiovascular diseases or
multiple diagnosis are more likely to pay out-of-pocket. Patients
with chronic disease have an average of $24.1 monthly spend-
ing and only 1.8% of them have to pay more than $100 monthly.
The spending rate is signiﬁcantly correlated with non-formulary
drugs (r = 0.48) and also associated with a single source brand
names. CONCLUSION: The data revealed a high rate of free
access to prescription drug for MOH beneﬁciaries and an accept-
able (<16.5 US dollar) out-of-pocket spending for 98% of the
patients who paid out-of-pocket. Although, there are multiple
and alternative sources for MOH beneﬁciaries to avoid out-of-
pocket spending, there is still vulnerable group that dose not
have alternative source and might have a potential to not offered
to pay out-of-pocket. MOH may use its resources and consider
this group to ﬁll their prescriptions with minimum cost by using
the hospital social work program to identify this group.
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OBJECTIVES: Medication adherence is a major obstacle to
overcome when treating chronic medical conditions. Many
factors can inﬂuence how well a medication regimen is complied
with, including patient demographics such as race. The aim of
this study was to determine how race can affect medication
adherence in Medicaid-enrolled patients with chronic disease.
METHODS: We examined the association between race and
controller medication adherence in confounder adjusted multi-
variate analyses on data from 3 retrospective cohorts enrolled in
the North Carolina Medicaid program. These cohorts included
patients with primary diagnoses of asthma (n = 710), type 2 dia-
betes (n = 2655), and psoriasis (n = 186). The data for these
studies was extrapolated from the North Carolina Medicaid
claims and eligibility ﬁles and patients were followed up for a
minimum of two years. RESULTS: The results were mixed across
disease states. In patients with type 2 we found that medication
adherence rates (using medication possession ratios) for oral
antidiabetics was signiﬁcantly higher for whites [59%] as com-
pared to African Americans [54%] (p < 0.05). Similarly, in
patients with asthma, we found that African American patients
were 65% less likely to have the recommended medication pos-
session rate of at least 80% [RR: 0.35, 95% CI: 0.15–0.81].
There were no signiﬁcant patient differentials in controller med-
ication adherence by race in patients with psoriasis. CONCLU-
SION: The results were mixed across disease states. In patients
with type 2 we found that medication adherence rates (using
medication possession ratios) for oral antidiabetics was signiﬁ-
cantly higher for whites [59%] as compared to African Ameri-
